Preclinical data reported by the Seattle group have demonstrated how CAR-T cells targeting tumor-associated ROR-1 can be prevented from inducing otherwise toxic abrogation of healthy bone marrow stromal tissue by endowing them with synthetic notch receptors (SynNotch) which specifically recognize EpCAM or B7-H3 leading to tumor regression while sparing healthy tissues (35). The gene discussed is ROR1; the disease is neoplasm.